Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation
← catalyst calendarNCT07628062 · readout in 1,595 d
Sponsored by ImmunityBio, Inc. (industry) · IBRX — their whole pipeline →.
Phase
Phase 2
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
70estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-22 | estimated | When the study began enrolling |
| Primary completion | 2030-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-06-27 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- HPV-Positive Oropharyngeal Squamous Cell Carcinoma
- Oropharyngeal Squamous Cell Carcinoma
- Head and Neck Cancer
Interventions
- Drug: Nogapendekin Alfa Inbakicept (NAI)
- Biological: hAd5-HPV Vaccine (IBRX-042)
- Drug: Nab-Paclitaxel
- Drug: Cisplatin
- Radiation: De-Intensified IMRT
- Radiation: Standard of Care IMRT
Primary outcome
what the primary-completion date above is the date OFProgression-Free Survival (PFS)
measured Up to approximately 2 years after completion of treatment
Permalink · IBRX's whole pipeline · Catalyst calendar · Every registered study · What changed